NEW YORK – Datar Cancer Genetics said on Monday that it has struck a $250 million contract with US diagnostic laboratory company Artemis DNA, which will provide Datar's cancer detection liquid biopsies in the US and Vietnam.
The five-year exclusive agreement covers two Datar cancer screening and diagnostic tests: Trucheck Pragma, a noninvasive, blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; and Cancertrack, which evaluates therapy response, resistance, and cancer recurrence in patients. The assays will be initially offered as laboratory-developed tests in the US, according to Datar.
In addition, Artemis DNA will provide Datar with CLIA-certified, CAP-accredited testing facilities in Texas and California to enable the commercial launch of various cancer screening and diagnostic tests developed by Datar.
"We are extremely delighted to offer our highly accurate cancer detection technology for the benefit of patients in the USA and Vietnam in partnership with Artemis DNA," Datar Cancer Genetics Chairman Rajan Datar said in a statement. "We will continue to expand our offerings in the USA and European markets with high standards of accuracy and quality of service."